Avacta Group plc (GB:AVCT) has released an update.
Avacta Group plc’s interim report highlights the promising clinical performance of its lead drug, AVA6000, which has shown favorable tolerability and preliminary efficacy in its Phase 1a trial. Financially, the company reports revenues of £11.3 million and an adjusted EBITDA loss of £11.1 million, alongside a successful fundraise of £31.1 million. Avacta is also pursuing strategic goals, including the sale of its Diagnostics division and exploring a NASDAQ dual listing to maximize shareholder value.
For further insights into GB:AVCT stock, check out TipRanks’ Stock Analysis page.
